Table 2.

Number of events at the end of follow-up of the 4D Study stratified by quartiles of oxalate concentration at baseline^a

Events	Quartile 1 ≤29.6 µM n=274	Quartile 2 29.7–42.3 µM n=279	Quartile 3 42.4–59.6 µM n=274	Quartile 4 ≥59.7 µM n=281
All-cause mortality (n=548)	121	142	134	151
Cardiovascular eventsb (n=413)	93	97	91	132
Sudden cardiac death (n=139)	26	35	37	41
Death due to heart failure (n=38)	7	8	9	14
Myocardial infarction (n=177)	39	44	37	57
Stroke (n=90)	25	16	17	32

^aThe median follow-up was 4.0 years in the atorvastatin arm and 4.1 years in the placebo arm.

^bCombined cardiovascular events were defined as a composite of death from cardiac causes, fatal or nonfatal stroke, and nonfatal myocardial infarction, whichever occurred first. Death from cardiac causes comprised death due to congestive heart failure, sudden cardiac death, fatal myocardial infarction, death due to coronary artery disease during or within 28 days after an intervention, and all other deaths attributable to coronary artery disease.